OmniAb (NASDAQ:OABI) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of OmniAb (NASDAQ:OABI) in a report released on Wednesday morning,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for OmniAb’s Q4 2025 earnings at ($0.15) EPS and FY2029 earnings at ($0.29) EPS.

OmniAb Stock Performance

Shares of OABI stock opened at $2.53 on Wednesday. The stock’s fifty day moving average is $3.34 and its 200-day moving average is $3.77. OmniAb has a 52 week low of $2.23 and a 52 week high of $5.63. The stock has a market capitalization of $357.28 million, a PE ratio of -4.08 and a beta of -0.14.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.01. OmniAb had a negative net margin of 308.78% and a negative return on equity of 20.97%. The firm had revenue of $10.80 million during the quarter, compared to analysts’ expectations of $10.13 million. During the same quarter last year, the company posted ($0.14) EPS. As a group, analysts forecast that OmniAb will post -0.61 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other OmniAb news, insider Charles S. Berkman sold 25,489 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total transaction of $82,584.36. Following the completion of the sale, the insider now directly owns 343,190 shares of the company’s stock, valued at approximately $1,111,935.60. The trade was a 6.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Matthew W. Foehr sold 41,811 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $135,467.64. Following the completion of the transaction, the chief executive officer now directly owns 3,749,639 shares in the company, valued at $12,148,830.36. This trade represents a 1.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 112,260 shares of company stock valued at $376,601. 8.60% of the stock is currently owned by corporate insiders.

Institutional Trading of OmniAb

Several institutional investors and hedge funds have recently made changes to their positions in OABI. Invesco Ltd. lifted its stake in OmniAb by 3.3% in the fourth quarter. Invesco Ltd. now owns 93,653 shares of the company’s stock valued at $332,000 after buying an additional 2,997 shares during the period. Connors Investor Services Inc. increased its stake in shares of OmniAb by 18.4% in the 4th quarter. Connors Investor Services Inc. now owns 29,611 shares of the company’s stock valued at $105,000 after acquiring an additional 4,611 shares during the last quarter. SG Americas Securities LLC increased its stake in shares of OmniAb by 16.5% in the 4th quarter. SG Americas Securities LLC now owns 40,609 shares of the company’s stock valued at $144,000 after acquiring an additional 5,751 shares during the last quarter. Sherbrooke Park Advisers LLC raised its position in shares of OmniAb by 53.5% in the 4th quarter. Sherbrooke Park Advisers LLC now owns 17,226 shares of the company’s stock valued at $61,000 after acquiring an additional 6,001 shares during the period. Finally, Isthmus Partners LLC boosted its stake in OmniAb by 1.6% during the 4th quarter. Isthmus Partners LLC now owns 453,135 shares of the company’s stock worth $1,604,000 after acquiring an additional 7,001 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.